Effects of PPARγ ligands on vascular tone

Current Molecular Pharmacology

Volumn 5, Issue 2, 2012, Pages 282-291

  Salomone, Salvatore ^a   Drago, Filippo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Pioglitazone; PPAR ; Rosiglitazone; Thiazolidinediones; Troglitazone; Vascular tone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CALCIUM CHANNEL L TYPE; CALCIUM ION; CALMODULIN; CYCLIC GMP; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MYOSIN LIGHT CHAIN KINASE; MYOSIN PHOSPHATASE TARGET SUBUNIT 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA LIGAND; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; POTASSIUM ION; ROSIGLITAZONE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TROGLITAZONE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD VESSEL DIAMETER; BLOOD VESSEL TONE; CALCIUM TRANSPORT; CARDIOVASCULAR RISK; CELL MEMBRANE DEPOLARIZATION; CHANNEL GATING; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GAP JUNCTION; GENETIC POLYMORPHISM; HEART MUSCLE CELL; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERFUSION PRESSURE; POTASSIUM CURRENT; PRIORITY JOURNAL; REVIEW; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE CELL; VASOCONSTRICTION; VASODILATATION;

EID: 84861750793     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205020282     Document Type: Review

References (105)

1. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 1990, 347, 645-650.
2. Michalik, L.; Auwerx, J.; Berger, J.P.; Chatterjee, V.K.; Glass, C.K.; Gonzalez, F.J.; Grimaldi, P.A.; Kadowaki, T.; Lazar, M.A.; O'Rahilly, S.; Palmer, C.N.; Plutzky, J.; Reddy, J.K.; Spiegelman, B.M.; Staels, B.; Wahli, W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev., 2006, 58, 726-741.
3. Ehrenborg, E.; Krook, A. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol. Rev., 2009, 61, 373-393.
4. Wang, Y.X.; Zhang, C.L.; Yu, R.T.; Cho, H.K.; Nelson, M.C.; Bayuga-Ocampo, C.R.; Ham, J.; Kang, H.; Evans, R.M. Regulation of muscle fiber type and running endurance by ppardelta. PLoS Biol., 2004, 2, e294.
5. Lee, C.H.; Chawla, A.; Urbiztondo, N.; Liao, D.; Boisvert, W.A.; Evans, R.M.; Curtiss, L.K. Transcriptional repression of atherogenic inflammation: Modulation by PPARdelta. Science, 2003, 302, 453-457.
6. Barish, G.D.; Atkins, A.R.; Downes, M.; Olson, P.; Chong, L.W.; Nelson, M.; Zou, Y.; Hwang, H.; Kang, H.; Curtiss, L.; Evans, R.M.; Lee, C.H. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc. Natl. Acad. Sci. USA, 2008, 105, 4271-4276.
7. Francis, G.A.; Fayard, E.; Picard, F.; Auwerx, J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol., 2003, 65, 261-311.
8. Watkins, P.B.; Whitcomb, R.W. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med., 1998, 338, 916-917.
9. Masubuchi, Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: A review. Drug Metab. Pharmacokinet., 2006, 21, 347-356.
10. Nissen, S.E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 2007, 356, 2457-2471.
11. Kaul, S.; Bolger, A.F.; Herrington D.; Giugliano R.P.; Eckel R.H. Thiazolidinedione drugs and cardiovascular risks: A science advisory from the american heart association and american college of cardiology foundation. Circulation, 2010, 121, 1868-1877.
12. Panigrahy, D.; Singer, S.; Shen, L.Q.; Butterfield, C.E.; Freedman, D.A.; Chen, E.J.; Moses, M.A.; Kilroy, S.; Duensing, S.; Fletcher, C.; Fletcher, J.A.; Hlatky, L.; Hahnfeldt, P., Folkman, J.; Kaipainen, A. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest., 2002, 110, 923-932.
13. Jiang, C.; Ting, A.T.; Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998, 391, 82-86.
14. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 1998, 391, 79-82.
15. Sigrist, S.; Bedoucha, M.; Boelsterli, U.A. Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mrna expression in a murine model of non-insulin-dependent diabetes. Biochem. Pharmacol., 2000, 60, 67-75.
16. Youssef, J.; Badr, M. Enhanced hepatocarcinogenicity due to agonists of peroxisome proliferator-activated receptors in senescent rats: Role of peroxisome proliferation, cell proliferation, and apoptosis. ScientificWorldJournal, 2002, 2, 1491-1500.
17. Schmidt, M.V.; Brune, B.; von Knethen, A. The nuclear hormone receptor ppargamma as a therapeutic target in major diseases. ScientificWorldJournal, 2010, 10, 2181-2197.
18. Heneka, M.T.; Landreth, G.E. PPARs in the brain. Biochim. Biophys. Acta., 2007, 1771, 1031-1045.
19. Balakumar, P.; Rose, M.; Ganti, S.S.; Krishan, P.; Singh, M. PPAR dual agonists: Are they opening pandora's box? Pharmacol. Res., 2007, 56, 91-98.
20. Schupp, M.; Janke, J.; Clasen, R.; Unger, T.; Kintscher, U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation., 2004, 109, 2054-2057.
21. Schupp, M.; Clemenz, M.; Gineste, R., Witt, H.; Janke, J.; Helleboid, S.; Hennuyer, N.; Ruiz, P.; Unger, T.; Staels, B.; Kintscher, U. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes, 2005, 54, 3442-3452.
22. van Bilsen, M.; van Nieuwenhoven, F.A. PPARs as therapeutic targets in cardiovascular disease. Expert. Opin. Ther. Targets, 2010, 14, 1029-1045.
23. Kaur, T.; Goel, R.K.; Balakumar, P. Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction. Arch. Pharm. Res., 2010, 33, 611-618.
24. Shin, H.K.; Salomone, S.; Ayata, C. Targeting cerebrovascular rhokinase in stroke. Expert Opin. Ther. Targets, 2008, 12, 547-1564.
25. Yoshioka, S.; Nishino, H.; Shiraki, T.; Ikeda, K.; Koike, H.; Okuno, A.; Wada, M.; Fujiwara, T.; Horikoshi, H. Antihypertensive effects of CS-045 treatment in obese zucker rats. Metabolism, 1993, 42, 75-80.
26. Jeninga, E.H.; Gurnell, M.; Kalkhoven, E. Functional implications of genetic variation in human PPARgamma. Trends Endocrinol. Metab., 2009, 20, 380-387.
27. Al-Shali, K.Z.; House, A.A.; Hanley, A.J.; Khan, H.M.; Harris, S.B.; Zinman, B.; Mamakeesick, M.; Fenster, A.; Spence, J.D.; Hegele, R.A. Genetic variation in PPARg encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke, 2004, 35, 2036-2040.
28. Gao, L.; Wang, L.; Yun, H.; Su, L.; Su, X. Association of the PPARgamma2 gene pro12ala variant with primary hypertension and metabolic lipid disorders in han chinese of inner mongolia. Genet. Mol. Res., 2010, 9, 1312-1320.
29. Underwood, P.C.; Sun, B.; Williams, J.S.; Pojoga, L.H.; Chamarthi, B.; Lasky-Su, J.; Raby, B.A.; Hopkins, P.N.; Jeunemaitre, X.; Brown, N.J.; Adler, G.K.; Williams, G.H. The relationship between peroxisome proliferator-activated receptorgamma and renin: A human genetics study. J. Clin. Endocrinol. Metab., 2010, 95, E75-79.
30. Nicol, C.J.; Adachi, M.; Akiyama, T.E.; Gonzalez, F.J. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am. J. Hypertens., 2005, 18, 549-556.
31. Wang, N.; Symons, J.D.; Zhang, H.; Jia, Z.; Gonzalez, F.J.; Yang, T. Distinct functions of vascular endothelial and smooth muscle ppargamma in regulation of blood pressure and vascular tone. Toxicol. Pathol., 2009, 37, 21-27.
32. Wang, N.; Yang, G.; Jia, Z.; Zhang, H.; Aoyagi, T.; Soodvilai, S.; Symons, J.D.; Schnermann, J.B.; Gonzalez, F.J.; Litwin, S.E.; Yang, T. Vascular PPARgamma controls circadian variation in blood pressure and heart rate through bmal1. Cell Metab., 2008, 8, 482-491.
33. Kleinhenz, J.M.; Kleinhenz, D.J.; You, S.; Ritzenthaler, J.D.; Hansen, J.M.; Archer, D.R.; Sutliff, R.L.; Hart, C.M. Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production. Am. J. Physiol. Heart Circ. Physiol., 2009, 297, H1647-1654.
34. Beyer, A.M.; de Lange, W.J.; Halabi, C.M.; Modrick, M.L.; Keen, H.L.; Faraci, F.M.; Sigmund, C.D. Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ. Res., 2008, 103, 654-661.
35. Halabi, C.M., Beyer, A.M.; de Lange, W.J.; Keen, H.L.; Baumbach, G.L.; Faraci, F.M.; Sigmund, C.D. Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab., 2008, 7, 215-226.
36. Chang, L.; Villacorta, L.; Zhang, J.; Garcia-Barrio, M.T.; Yang, K.; Hamblin, M.; Whitesall, S.E.; D'Alecy, L.G.; Chen, Y.E. Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension. Circulation, 2009, 119, 2161-2169.
37. Maltarollo, V.G.; Homem-de-Mello, P.; Honorio, K.M. Theoretical study on the molecular and electronic properties of some substances used for diabetes mellitus treatment. J. Mol. Model., 2010, 16, 799-804.
38. Sears, D.D.; Hsiao, A.; Ofrecio, J.M.; Chapman, J.; He, W.; Olefsky, J.M. Selective modulation of promoter recruitment and transcriptional activity of PPARgamma. Biochem. Biophys. Res. Commun., 2007, 364, 515-521.
39. Pomel, V.; Klicic, J.; Covini, D.; Church, D.D.; Shaw, J.P.; Roulin, K.; Burgat-Charvillon, F.; Valognes, D.; Camps, M.; Chabert, C.; Gillieron, C.; Francon, B.; Perrin, D.; Leroy, D.; Gretener, D.; Nichols, A.; Vitte, P.A.; Carboni, S.; Rommel, C.; Schwarz, M.K.; Ruckle, T. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J. Med. Chem. 2006, 49, 3857-3871.
40. Oudit, G.Y.; Sun, H.; Kerfant, B.G.; Crackower, M.A.; Penninger, J.M.; Backx, P.H. The role of phosphoinositide-3 kinase and pten in cardiovascular physiology and disease. J. Mol. Cell. Cardiol., 2004, 37, 449-471.
41. Alloatti, G.; Montrucchio, G.; Lembo, G.; Hirsch, E. Phosphoinositide 3-kinase gamma: Kinase-dependent and-independent activities in cardiovascular function and disease. Biochem. Soc. Trans., 2004, 32, 383-386.
42. Atochin, D.N.; Wang, A.; Liu, V.W.; Critchlow, J.D.; Dantas, A.P.; Looft-Wilson, R.; Murata, T.; Salomone, S.; Shin, H.K.; Ayata, C.; Moskowitz, M.A.; Michel, T.; Sessa, W.C.; Huang, P.L. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J. Clin. Invest., 2007, 117, 1961-1967.
43. Somlyo, A.P.; Somlyo, A.V. Signal transduction and regulation in smooth muscle. Nature, 1994, 372, 231-236.
44. Godfraind, T.; Miller, R.; Wibo, M. Calcium antagonism and calcium entry blockade. Pharmacol. Rev., 1986, 38, 321-416.
45. Buchanan, T.A.; Meehan, W.P.; Jeng, Y.Y.; Yang, D.; Chan, T.M.; Nadler, J.L.; Scott, S.; Rude, R.K.; Hsueh, W.A. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J. Clin. Invest., 1995, 96, 354-360.
46. Pancani, T.; Phelps, J.T.; Searcy, J.L.; Kilgore, M.W.; Chen, K.C.; Porter, N.M.; Thibault, O. Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. J. Neurochem., 2009, 109, 1800-1811.
47. Majeed, Y.; Bahnasi, Y.; Seymour, V.A.; Wilson, L.A.; Milligan, C.J.; Agarwal, A.K.; Sukumar, P.; Naylor, J.; Beech, D.J. Rapid and contrasting effects of rosiglitazone on TRPM3 and TRPC5 channels. Mol. Pharmacol., 2011
48. Eto, K.; Ohya, Y.; Nakamura, Y.; Abe, I.; Fujishima, M. Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur. J. Pharmacol., 2001, 423, 1-7.
49. Heppner, T.J.; Bonev, A.D.; Eckman, D.M.; Gomez, M.F.; Petkov, G.V.; Nelson, M.T. Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. Pharmacology, 2005, 73, 15-22.
50. Ko, E.A.; Han, J.; Jung, I.D.; Park, W.S. Physiological roles of K+ channels in vascular smooth muscle cells. J. Smooth Muscle Res., 2008, 44, 65-81.
51. Rotte, A.; Mack, A.F.; Bhandaru, M.; Kempe, D.S.; Beier, N.; Scholz, W.; Dicks, E.; Potzsch, S.; Kuhl, D.; Lang, F. Pioglitazone induced gastric acid secretion. Cell Physiol. Biochem., 2009, 24, 193-200.
52. Bajwa, P.J.; Lee, J.W.; Straus, D.S.; Lytle, C. Activation of PPARgamma by rosiglitazone attenuates intestinal Cl-secretion. Am. J. Physiol. Gastrointest. Liver. Physiol., 2009, 297, G82-89.
53. Wu, S.N.; Ho, L.L.; Li, H.F.; Chiang, H.T. Regulation of CA(2+)-activated K+ currents by ciglitazone in rat pituitary GH3 cells. J. Investig. Med., 2000, 48, 259-269.
54. Shimomura, K.; Shimizu, H.; Ikeda, M.; Okada, S.; Kakei, M.; Matsumoto, S.; Mori, M. Fenofibrate, troglitazone, and 15-deoxydelta12,14-prostaglandin J2 close KATP channels and induce insulin secretion. J. Pharmacol. Exp. Ther., 2004, 310, 1273-1280.
55. Scarsi, M.; Podvinec, M.; Roth, A.; Hug, H.; Kersten, S.; Albrecht, H.; Schwede, T.; Meyer, U.A.; Rucker, C. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: A combined virtual screening and biological assay approach. Mol. Pharmacol., 2007, 71, 398-406.
56. Kim, K.Y.; Cheon, H.G. Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gammaactivated maxi-K channel opening in human umbilical vein endothelial cells. J. Biol. Chem., 2006, 281, 13503-13512.
57. Kinoshita, H.; Azma, T.; Iranami, H.; Nakahata, K.; Kimoto, Y.; Dojo, M.; Yuge, O.; Hatano, Y. Synthetic peroxisome proliferatoractivated receptor-gamma agonists restore impaired vasorelaxation via ATP-sensitive K+ channels by high glucose. J. Pharmacol. Exp. Ther., 2006, 318, 312-318.
58. Nomura, H.; Yamawaki, H.; Mukohda, M.; Okada, M.; Hara, Y. Mechanisms underlying pioglitazone-mediated relaxation in isolated blood vessel. J. Pharmacol. Sci., 2008, 108, 258-265.
59. Somlyo, A.P.; Somlyo, A.V. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: Modulated by g proteins, kinases, and myosin phosphatase. Physiol. Rev., 2003, 83, 1325-1358.
60. Wilson, D.P.; Sutherland, C.; Borman, M.A.; Deng, J.T.; Macdonald, J.A.; Walsh, M.P. Integrin-linked kinase is responsible for Ca2+-independent myosin diphosphorylation and contraction of vascular smooth muscle. Biochem. J., 2005, 392, 641-648.
61. Somlyo, A.P.; Somlyo, A.V. Smooth muscle: Excitationcontraction coupling, contractile regulation, and the cross-bridge cycle. Alcohol Clin. Exp. Res., 1994, 18, 138-143.
62. Schubert, R.; Lidington, D.; Bolz, S.S. The emerging role of Ca2+ sensitivity regulation in promoting myogenic vasoconstriction. Cardiovasc. Res., 2008, 77, 8-18.
63. Wakino, S.; Hayashi, K.; Kanda, T.; Tatematsu, S.; Homma, K.; Yoshioka, K.; Takamatsu, I.; Saruta, T. Peroxisome proliferatoractivated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ. Res., 2004, 95, e45-55.
64. Atkins, K.B.; Irey, B.; Xiang, N.; Brosius, F.C. 3rd. A rapid, PPAR-gamma-dependent effect of pioglitazone on the phosphorylation of MYPT. Am. J. Physiol. Cell Physiol., 2009, 296, C1151-1161.
65. Salomone, S. Pleiotropic effects of glitazones: A double edge sword? Front. Pharmacol., 2011, 2, 14
66. Ryan, M.J.; Didion, S.P.; Mathur, S.; Faraci, F.M.; Sigmund, C.D. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension, 2004, 43, 661-666.
67. Sprague, A.H.; Khalil, R.A. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol., 2009, 78, 539-552.
68. Ricote, M.; Huang, J.; Fajas, L.; Li A.; Welch, J.; Najib, J.; Witztum, J.L.; Auwerx, J.; Palinski, W.; Glass, C.K. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA, 1998, 95, 7614-7619.
69. Yang, X.Y.; Wang, L.H.; Chen, T.; Hodge, D.R.; Resau, J.H.; DaSilva, L.; Farrar, W.L. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J. Biol. Chem., 2000, 275, 4541-4544.
70. Wang, N.; Verna, L.; Chen, N.G.; Chen, J.; Li, H.; Forman, B.M.; Stemerman, M.B. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses proinflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem., 2002, 277, 34176-34181.
71. Marx, N.; Mach, F.; Sauty, A.; Leung, J.H.; Sarafi, M.N.; Ransohoff, R.M.; Libby, P.; Plutzky, J.; Luster, A.D. Peroxisome proliferator-activated receptor-gamma activators inhibit IFNgamma-induced expression of the T cell-active CXC chemokines IP-10, MIG, and I-TAC in human endothelial cells. J. Immunol., 2000, 164, 6503-6508.
72. Verrier, E.; Wang, L.; Wadham, C.; Albanese, N.; Hahn, C.; Gamble, J.R.; Chatterjee, V.K.; Vadas, M.A.; Xia, P. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase c signaling pathway: Role of diacylglycerol kinase. Circ. Res., 2004, 94, 1515-1522.
73. Ji, Y.; Liu, J.; Wang, Z.; Liu, N.; Gou, W. PPARgamma agonist, rosiglitazone, regulates angiotensin ii-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab. Invest., 2009, 89, 887-902.
74. Lombardi, A.; Cantini, G.; Piscitelli, E.; Gelmini, S.; Francalanci, M.; Mello, T.; Ceni, E.; Varano, G.; Forti, G.; Rotondi, M.; Galli, A.; Serio, M.; Luconi, M. A new mechanism involving erk contributes to rosiglitazone inhibition of tumor necrosis factoralpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 718-724.
75. Diep, Q.N.; El Mabrouk, M.; Cohn, J.S.; Endemann, D.; Amiri, F.; Virdis, A.; Neves, M.F.; Schiffrin, E.L. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: Role of peroxisome proliferatoractivated receptor-gamma. Circulation, 2002, 105, 2296-2302.
76. Jones, A.; Deb, R.; Torsney, E.; Howe, F.; Dunkley, M.; Gnaneswaran, Y.; Gaze, D.; Nasr, H.; Loftus, I.M.; Thompson, M.M.; Cockerill, G.W. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation, 2009, 119, 3125-3132.
77. Pasceri, V.; Wu, H.D.; Willerson, J.T.; Yeh, E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation, 2000, 101, 235-238.
78. Jackson, S.M.; Parhami, F.; Xi, X.P.; Berliner, J.A.; Hsueh, W.A.; Law, R.E.; Demer, L.L. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyteendothelial cell interaction. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 2094-2104.
79. Bishop-Bailey, D.; Hla, T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-delta12, 14-prostaglandin J2. J. Biol. Chem., 1999, 274, 17042-17048.
80. Inoue, I.; Hayashi, K.; Yagasaki, F.; Nakamura, K.; Matsunaga, T.; Xu, H.; Inukai, K.; Awata, T.; Komoda, T.; Katayama, S. Apoptosis of endothelial cells may be mediated by genes of peroxisome proliferator-activated receptor gamma 1 (PPARgamma 1) and PPARalpha genes. J. Atheroscler. Thromb., 2003, 10, 99-108.
81. Hannan, K.M.; Dilley, R.J.; de Dios, S.T.; Little, P.J. Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 762-768.
82. Xin, X., Yang, S., Kowalski, J., Gerritsen, M.E. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem., 1999, 274, 9116-9121.
83. Goetze, S.; Eilers, F.; Bungenstock, A.; Kintscher, U.; Stawowy, P.; Blaschke, F.; Graf, K.; Law, R.E.; Fleck, E; Grafe, M. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem. Biophys. Res. Commun., 2002, 293, 1431-1437.
84. Goetze, S.; Bungenstock, A.; Czupalla, C.; Eilers, F.; Stawowy, P.; Kintscher, U.; Spencer-Hansch, C.; Graf K.; Nurnberg, B.; Law, R.E.; Fleck, E., Grafe, M. Leptin induces endothelial cell migration through akt, which is inhibited by PPARgamma-ligands. Hypertension, 2002, 40, 748-754.
85. Biscetti, F.; Straface, G.; Pitocco, D.; Zaccardi, F.; Ghirlanda, G.; Flex, A. Peroxisome proliferator-activated receptors and angiogenesis. Nutr. Metab. Cardiovasc. Dis., 2009, 19, 751-759.
86. Shen, L.Q.; Child, A.; Weber, G.M.; Folkman, J.; Aiello, L.P. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch. Ophthalmol., 2008, 126, 793-799.
87. Simpson-Haidaris, P.J.; Pollock, S.J.; Ramon, S.; Guo, N.; Woeller, C.F.; Feldon, S.E.; Phipps, R.P. Anticancer role of ppargamma agonists in hematological malignancies found in the vasculature, marrow, and eyes. PPAR Res., 2010, 2010, 814609.
88. Reka, A.K.; Goswami, M.T.; Krishnapuram, R.; Standiford, T.J.; Keshamouni, V.G. Molecular cross-regulation between PPARgamma and other signaling pathways: Implications for lung cancer therapy. Lung Cancer, 2011, 72, 154-159.
89. Soskic, S.S.; Dobutovic, B.D.; Sudar, E.M.; Obradovic, M.M.; Nikolic, D.M., Zaric, BL; Stojanovic S.D.; Stokic E.J.; Mikhailidis D.P.; Isenovic E.R. The peroxisome proliferator-activated receptors and atherosclerosis. Angiology, 2011, 62(7), 523-534.
90. Delerive, P.; Martin-Nizard, F.; Chinetti, G.; Trottein, F.; Fruchart, J.C.; Najib, J.; Duriez, P.; Staels, B. Peroxisome proliferatoractivated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res., 1999, 85, 394-402.
91. Calnek, D.S.; Mazzella, L.; Roser, S.; Roman, J.; Hart, C.M. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 52-57.
92. Polikandriotis, J.A.; Mazzella, L.J.; Rupnow, H.L.; Hart, C.M. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1810-1816.
93. Hwang, J.; Kleinhenz, D.J.; Lassegue, B.; Griendling, K.K.; Dikalov, S.; Hart, C.M. Peroxisome proliferator-activated receptorgamma ligands regulate endothelial membrane superoxide production. Am. J. Physiol. Cell. Physiol., 2005, 288, C899-905.
94. Iglarz, M.; Touyz, R.M.; Amiri, F.; Lavoie, M.F.; Diep, Q.N.; Schiffrin, E.L. Effect of peroxisome proliferator-activated receptoralpha and-gamma activators on vascular remodeling in endothelindependent hypertension. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 45-51.
95. Abe, M.; Hasegawa, K.; Wada, H.; Morimoto, T.; Yanazume, T.; Kawamura, T.; Hirai, M.; Furukawa, Y.; Kita, T. Gata-6 is involved in ppargamma-mediated activation of differentiated phenotype in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 404-410.
96. Bishop-Bailey, D.; Hla, T.; Warner, T.D. Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptorgamma ligand therapy. Circ. Res., 2002, 91, 210-217.
97. Wakino, S., Kintscher, U., Kim, S., Yin, F., Hsueh, W.A., Law, R.E. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and g1--> s transition in vascular smooth muscle cells. J. Biol. Chem., 2000, 275, 22435-22441.
98. Bruemmer, D.; Berger, J.P.; Liu, J.; Kintscher, U.; Wakino, S.; Fleck, E.; Moller, D.E.; Law R.E. A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. Eur. J. Pharmacol., 2003, 466, 225-234.
99. de Dios, S.T.; Bruemmer, D.; Dilley, R.J.; Ivey, M.E.; Jennings, G.L.; Law, R.E.; Little, P.J. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptorgamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation, 2003, 107, 2548-2550.
100. Bruemmer, D.; Yin, F.; Liu, J.; Berger, J.P.; Sakai, T.; Blaschke, F.; Fleck, E.; Van Herle, A.J.; Forman, B.M.; Law, R.E. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circ. Res., 2003, 93, e38-47.
101. Takeda, K.; Ichiki, T.; Tokunou, T.; Funakoshi, Y.; Iino, N.; Hirano, K.; Kanaide, H.; Takeshita, A. Peroxisome proliferatoractivated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation, 2000, 102, 1834-1839.
102. Barlic, J.; Murphy, P.M. An oxidized lipid-peroxisome proliferatoractivated receptor gamma-chemokine pathway in the regulation of macrophage-vascular smooth muscle cell adhesion. Trends Cardiovasc. Med., 2007, 17, 269-274.
103. Chen, L., Yang, B., McNulty, J.A., Clifton, L.G., Binz, J.G., Grimes, A.M., Strum, J.C., Harrington, W.W., Chen, Z., Balon, T.W., Stimpson, S.A., Brown, K.K. Gi262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J. Pharmacol. Exp. Ther., 2005, 312, 718-725.
104. Sotiropoulos, K.B.; Clermont, A.; Yasuda, Y.; Rask-Madsen, C.; Mastumoto, M.; Takahashi, J.; Della Vecchia, K.; Kondo, T.; Aiello, L.P.; King, G.L. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase c activation: Novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J., 2006, 20, 1203-1205.
105. Geese, W.J.; Achanzar, W.; Rubin, C.; Hariharan, N.; Cheng, P.; Tomlinson, L.; Ordway, N.; Dracopoli, N.C.; Delmonte, T.; Hui, L.; Krishnan, B.; Cosma, G.; Ranade, K. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists. Pharmacogenet. Genomics, 2008, 18, 903-910.